Analysis Tools|
Allele Symbol Allele Name Allele ID |
Tg(MMTV-vHaras)SH1Led transgene insertion SH1, Philip Leder MGI:2447530 |
||||||||||||||||||||||||||||||||||||
| Summary |
8 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice develop mammary and salivary tumors with a latency of 60 weeks compared to 18 weeks in Tg(MMTV-vHaras)SH1Led transgenic mice
• 10% of mice do not develop tumors within 2 years of observation
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• all mutants developed mammary gland tumors however the average age of tumor onset was 37 weeks compared to 25 weeks in control transgenic mice that are wildtype for Mmp11
• mean time required to develop detectable tumor after the first pregnancy was about 10 weeks longer than in control transgenic mice that are wildtype for Mmp11
• decreased invasive primary tumor incidence compared to control transgenic mice that are wildtype for Mmp11
|
|
• 69% developed lung metastases compared to 31% of control transgenic mice that are wildtype for Mmp11
• higher total number of metastases compared to transgenic mice that are wildtype for Mmp11
|
|
• mean tumor number per mouse was about 40% lower than in control transgenic mice that are wildtype for Mmp11
• mean total tumor volume was about 2-fold lower than in control transgenic mice that are wildtype for Mmp11
|
|
• developed tumors of various sizes that corresponded to moderately to poorly differentiated invasive duct carcinomas with most tumors growing as solid areas that contained no stroma
|
|
• all mutants developed mammary gland tumors however the average age of tumor onset was 37 weeks compared to 25 weeks in control transgenic mice that are wildtype for Mmp11
• mean time required to develop detectable tumor after the first pregnancy was about 10 weeks longer than in control transgenic mice that are wildtype for Mmp11
• decreased invasive primary tumor incidence compared to control transgenic mice that are wildtype for Mmp11
|
|
• all mutants developed mammary gland tumors however the average age of tumor onset was 37 weeks compared to 25 weeks in control transgenic mice that are wildtype for Mmp11
• mean time required to develop detectable tumor after the first pregnancy was about 10 weeks longer than in control transgenic mice that are wildtype for Mmp11
• decreased invasive primary tumor incidence compared to control transgenic mice that are wildtype for Mmp11
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• exhibit increased tumor multiplicity and aggressiveness, however, once tumors appear, their growth rate, apoptosis level, and mitotic index are not affected
|
|
• by 63 days of age, all mice develop either malignant (mammary and/or salivary adenocarcinomas) or benign (Harderian hyperplasia) tumors, compared to only 1 of 9 controls expressing only the Tg(MMTV-vHaras)SH1Led transgene
|
|
• by 63 days of age, all mice develop either malignant (mammary and/or salivary adenocarcinomas) or benign (Harderian hyperplasia) tumors, compared to only 1 of 9 controls expressing only the Tg(MMTV-vHaras)SH1Led transgene
• by 94 days of age, 50% develop mammary tumors compared to none of the controls
• by 4 months of age, the mammary tumor multiplicity is 10-fold greater than in controls
|
|
• exhibit earlier onset of tumors
|
|
• by 63 days of age, all mice develop either malignant (mammary and/or salivary adenocarcinomas) or benign (Harderian hyperplasia) tumors, compared to only 1 of 9 controls expressing only the Tg(MMTV-vHaras)SH1Led transgene
|
|
• by 63 days of age, all mice develop either malignant (mammary and/or salivary adenocarcinomas) or benign (Harderian hyperplasia) tumors, compared to only 1 of 9 controls expressing only the Tg(MMTV-vHaras)SH1Led transgene
• by 94 days of age, 50% develop mammary tumors compared to none of the controls
• by 4 months of age, the mammary tumor multiplicity is 10-fold greater than in controls
|
|
• enlargement of the glands is evident as early as 5 weeks after birth, with glands reaching up to 20 times their normal weight by 4 months of age
|
|
• 100% of mutants exhibit bilateral hyperplasia of the Harderian lacrimal glands by 63 days of age
|
|
• splenomegaly is due to a moderate to marked extramedullary hematopoiesis
|
|
• extramedullary hematopoiesis, frequently displaying atypical lymphoid cells and megakariocytes, results in splenomegaly
|
|
• splenomegaly is due to a moderate to marked extramedullary hematopoiesis
|
|
• by 63 days of age, all mice develop either malignant (mammary and/or salivary adenocarcinomas) or benign (Harderian hyperplasia) tumors, compared to only 1 of 9 controls expressing only the Tg(MMTV-vHaras)SH1Led transgene
|
|
• by 63 days of age, all mice develop either malignant (mammary and/or salivary adenocarcinomas) or benign (Harderian hyperplasia) tumors, compared to only 1 of 9 controls expressing only the Tg(MMTV-vHaras)SH1Led transgene
• by 94 days of age, 50% develop mammary tumors compared to none of the controls
• by 4 months of age, the mammary tumor multiplicity is 10-fold greater than in controls
|
|
• by 63 days of age, all mice develop either malignant (mammary and/or salivary adenocarcinomas) or benign (Harderian hyperplasia) tumors, compared to only 1 of 9 controls expressing only the Tg(MMTV-vHaras)SH1Led transgene
|
|
• splenomegaly is due to a moderate to marked extramedullary hematopoiesis
|
|
• by 63 days of age, all mice develop either malignant (mammary and/or salivary adenocarcinomas) or benign (Harderian hyperplasia) tumors, compared to only 1 of 9 controls expressing only the Tg(MMTV-vHaras)SH1Led transgene
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice exhibit no effect on the timing or multiplicity of tumor formation, which is largely restricted to mammary and salivary glands, however, once tumors appear, they grow faster than in controls
• the increase in growth rate of induced tumors is particularly striking for salivary tumors
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• by 17 weeks of age, mice exhibit multifocal nodules in the mammary gland and mammary intraepithelial neoplasia lesions
|
|
• by 40 weeks of age
|
|
• by 17 weeks of age, mice exhibit multifocal nodules in the mammary gland and mammary intraepithelial neoplasia lesions
|
|
• by 40 weeks of age
|
|
• by 17 weeks of age, mice exhibit multifocal nodules in the mammary gland and mammary intraepithelial neoplasia lesions
|
|
• by 40 weeks of age
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• only a small proportion of mice older than 35 weeks exhibit mammary intraepithelial neoplasia lesions and mammary tumors compared with Tg(MMTV-vHaras)SH1Led mice
• development of palpable breast tumors is delayed 26 weeks compared with Tg(MMTV-vHaras)SH1Led mice
• by 80 weeks, 25% of mice develop breast tumors compared with all Tg(MMTV-vHaras)SH1Led mice
• ovariectomized mice exhibit complete suppression of breast tumor development
|
|
• breast tumors exhibit decreased metastases compared with tumors from Tg(MMTV-vHaras)SH1Led mice
|
|
• breast tumors are smaller in size and exhibit slower growth than tumors from Tg(MMTV-vHaras)SH1Led mice
|
|
• mice exhibit delayed hormone-stimulated (via pituitary transplantation) mammary tumorigenesis compared with Tg(MMTV-vHaras)SH1Led mice
|
|
• breast tumor cells exhibit decreased migration compared with wild-type cells
|
 |
• mammary terminal end buds exhibit decreased proliferation compared to in Tg(MMTV-vHaras)SH1Led mice
• cell proliferation in hyperplasia, mammary intraepithelial neoplasia, and tumor lesions is less than in Tg(MMTV-vHaras)SH1Led mice
|
|
|
• mammary terminal end buds exhibit decreased proliferation compared to in Tg(MMTV-vHaras)SH1Led mice
• cell proliferation in hyperplasia, mammary intraepithelial neoplasia, and tumor lesions is less than in Tg(MMTV-vHaras)SH1Led mice
|
|
• only a small proportion of mice older than 35 weeks exhibit mammary intraepithelial neoplasia lesions and mammary tumors compared with Tg(MMTV-vHaras)SH1Led mice
• development of palpable breast tumors is delayed 26 weeks compared with Tg(MMTV-vHaras)SH1Led mice
• by 80 weeks, 25% of mice develop breast tumors compared with all Tg(MMTV-vHaras)SH1Led mice
• ovariectomized mice exhibit complete suppression of breast tumor development
|
| N |
• by 80 weeks of age, 50% of mice exhibit normal mammary gland morphology
|
|
|
• mammary terminal end buds exhibit decreased proliferation compared to in Tg(MMTV-vHaras)SH1Led mice
• cell proliferation in hyperplasia, mammary intraepithelial neoplasia, and tumor lesions is less than in Tg(MMTV-vHaras)SH1Led mice
|
|
• only a small proportion of mice older than 35 weeks exhibit mammary intraepithelial neoplasia lesions and mammary tumors compared with Tg(MMTV-vHaras)SH1Led mice
• development of palpable breast tumors is delayed 26 weeks compared with Tg(MMTV-vHaras)SH1Led mice
• by 80 weeks, 25% of mice develop breast tumors compared with all Tg(MMTV-vHaras)SH1Led mice
• ovariectomized mice exhibit complete suppression of breast tumor development
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• 31% developed lung metastases
|
|
• developed tumors of various sizes that corresponded to moderately to poorly differentiated invasive duct carcinomas with most tumors growing as solid areas that contained no stroma
• some of the largest tumors were infiltrated by hemorrhage, resulting in a microcystic growth pattern
|
|
• developed mammary gland tumors between 20 to 45 weeks of age with the mean age for onset at 25 weeks
|
|
• developed mammary gland tumors between 20 to 45 weeks of age with the mean age for onset at 25 weeks
|
|
• developed mammary gland tumors between 20 to 45 weeks of age with the mean age for onset at 25 weeks
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• at age 14 and 18 weeks, mice develop palpable breast tumors
• by 33 weeks of age, 50% of mice develop breast tumors
• by 70 weeks, all mice develop breast tumors
|
|
• at age 14 and 18 weeks, mice develop palpable breast tumors
• by 33 weeks of age, 50% of mice develop breast tumors
• by 70 weeks, all mice develop breast tumors
|
|
• at age 14 and 18 weeks, mice develop palpable breast tumors
• by 33 weeks of age, 50% of mice develop breast tumors
• by 70 weeks, all mice develop breast tumors
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 11/12/2024 MGI 6.24 |
|
|
|
||
